Comparison of Application Value of Erythropoietin and Roxallistat in the Treatment of Hemodialysis Renal Anemia in Chronic Renal Failure
Objective To compare the effect of erythropoietin and roxallistat in patients with chronic renal failure and hemodialysis renal anemia.Methods A total of 84 patients with chronic renal failure and hemodialysis renal anemia treated in Liupanshui Shougang Shuigang Hospital from March 2021 to March 2023 were conveniently selected as the study objects and divided into two groups according to random number table method,with 42 patients in each group.The control group treated with erythropoietin and the observation group treated with Roxallistat for 3 months.The therapeutic effect of the two groups was compared.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,Observation group hemoglobin was(105.36±12.45)g/L,red blood cell count was(3.56±0.99)×1012/L,hematocrit was(36.71±6.25)%,serum ferritin was(287.41±23.26)µg/L,transferrin was(2.98±0.83)g/L and transferrin Saturation was(35.21±3.88)%,those were higher than(88.72±10.42)g/L,(2.76±0.83)×1012/L,(29.84±4.46)%,(218.69±18.65)µg/L,(2.41±0.67)g/L,(26.84±3.41)%of control group,and ferrimodulin was(96.42±9.21)ng/mL,lower than that of control group(118.53±12.20)ng/mL,and the differences were statistically significant(t=6.642,4.013,5.799,14.938,3.463,10.501,9.374,all P<0.05).There was no significant difference in total ancidence of adverse reactions between the two groups(P>0.05).Conclusion Roxallistat can also improve the anemia status in patients with chronic renal failure and hemodialysis renal anemia,regulate iron metabolism without serious adverse reactions.
NETL
NSTL
万方数据
